Clinical Trial Equipment & Ancillary Solutions Market (2025 - 2033)

Clinical Trial Equipment & Ancillary Solutions Market Summary

The global clinical trial equipment & ancillary solutions market size was valued at USD 3.21 billion in 2024 and is projected to reach USD 6.88 billion by 2033, growing at a CAGR of 8.92% from 2025 to 2033. The growth of the market is due to the increasing complexity and globalization of clinical trials, which demand highly specialized, protocol-specific equipment and logistics support.

The rapid adoption of decentralized and hybrid trial models requires remote monitoring devices, wearable sensors, and home-use diagnostic kits, significantly expanding the scope of ancillary services. The transformation of clinical trial models, especially the increase of decentralized and hybrid trials, has significantly raised the demand for specialized equipment and support services that facilitate remote, site-less, and home-based research settings. The traditional model, which relied heavily on centralized trial sites, is being replaced by more patient-focused approaches, requiring remote monitoring devices, mobile health kits, wearables, and courier-enabled logistics for biological samples. For example, the U.S. FDA has promoted decentralized clinical trials (DCTs) through its 2023 draft guidance, urging sponsors to adopt digital health technologies and remote care tools to enhance patient access and data quality. These developments are leading CROs and sponsors to acquire reliable, temperature-sensitive packaging, validated medical devices for home use, and real-time tracking systems to oversee equipment shipments across different regions. This shift has transformed the role of clinical trial equipment suppliers from passive vendors into active, integrated service partners responsible for ensuring regulatory compliance, proper calibration, and delivery schedules aligned with study protocols.

Additionally, government and non-profit funding organizations are increasingly supporting early-stage research, translational medicine, and investigator-initiated trials, all of which depend on timely access to ancillary trial supplies. Initiatives like the NIH’s All of Us Research Program and the European Union’s Horizon Europe framework are expanding the boundaries of patient cohort diversity and precision diagnostics, which require adaptive and flexible equipment supply strategies. For example, Horizon Europe allocates nearly USD 111.49 billion (€95 billion) toward science and innovation through 2027, with multiple projects focused on personalized medicine, wearable monitoring, and telehealth-integrated clinical trials. These initiatives generate demand for site-ready kits, cloud-connected monitoring devices, and digitally traceable shipping for reagents and biologics.

Opportunity Analysis

Technological Advancements

The global clinical trial equipment and ancillary solutions market is rapidly changing, driven by innovations that improve efficiency, compliance, and patient engagement. Digital integration leads the way, with cloud-based inventory systems, IoT-enabled tracking devices, and AI-powered demand forecasting tools becoming more common. Wearable health technology, remote monitoring devices, and smart kits enable seamless data collection and decrease the need for on-site visits in decentralized trials. Automation in equipment calibration, temperature-controlled logistics, and packaging validation boosts accuracy and reduces manual work. Additionally, blockchain and RFID technologies are being explored to ensure secure, transparent, and traceable handling of critical clinical supplies across regions. This move toward connected, smart systems not only streamlines trial operations but also creates new opportunities for vendors to deliver bundled, end-to-end ancillary solutions tailored to modern trial needs.

Pricing Analysis

Type Insights

On the basis of type segment, the market is classified into sourcing, supply/logistics, service, and others. The supply/logistics segment accounted for the largest revenue share in the clinical trials equipment & ancillary solutions industry of 36.9% in 2024. The growth of the segment is due to increasing complexity and globalization of clinical trials. As trials expand to multiple regions, including emerging markets in Asia-Pacific, Latin America, and Eastern Europe-demand has surged for reliable cold chain logistics, time-sensitive deliveries, and compliant transport of temperature-sensitive and perishable supplies.

The sourcing segment is anticipated to grow at a considerable CAGR during the forecast period. The segment growth is driven due to the rising complexity of trial protocols and the increasing diversity of required ancillary materials. Clinical trials today require a wide array of equipment, including wearable devices, point-of-care diagnostics, customized sample kits, and region-specific medical supplies-prompting sponsors and CROs to outsource sourcing functions to specialized vendors with global procurement networks.

Phase Insights

Based on phase segmentation, the market is divided into Phase I, Phase II, Phase III, and Phase IV. The Phase III segment held the largest market share in 2024 due to its extensive scale, longer duration, and complex logistical needs. Phase III trials typically involve large patient populations across multiple geographic regions, requiring high volumes of medical equipment, diagnostic kits, and ancillary supplies. This phase also requires strong supply chain coordination to ensure consistent availability of calibrated devices, biosample kits, and temperature-sensitive materials at each trial site.

The Phase I segment is expected to grow at the fastest CAGR during the forecast period. Its growth is driven by an increase in early-stage clinical trials, especially in oncology, rare diseases, and cell and gene therapies. These trials often need specialized and customized equipment, such as first-in-human (FIH) dosing kits, rapid-response biosample collection tools, and highly controlled infusion devices, all requiring precise sourcing and handling.

Regional Insights

North America dominated the market with the largest market share of 40.46% in 2024, owing to the increased R&D investments, the presence of global players, and rising efforts to come up with newer patents. In addition, the increasing number of clinical trials is also fueling market growth.

U.S. Clinical Trial Equipment & Ancillary Solutions Market Trends

The clinical trial equipment & ancillary solutions market in the U.S. held the largest share in 2024. This is attributed to the increasing number of clinical trials being performed in the U.S. For instance, according to the National Clinical Trials Registry (NCT), around 12,326 clinical trials studies were undergoing across various phases for the treatment of cancer in 2022.

Europe Clinical Trial Equipment & Ancillary Solutions Market Trends

The clinical trial equipment & ancillary solutions market in Europe is expected to grow significantly due to rising focus on clinical trial studies, favorable government initiatives and policies, compliance with the Good Clinical Practice (GCP) standards, larger patient pools and rising number of clinical trials are some of the key factors fueling the market growth.

The clinical trial equipment & ancillary solutions market in Germany is driven by the factors such as advanced medical expertise and easy access to patients, low rate of saturation of competing trials, and high number of participants contributing to the clinical research studies.

The clinical trial equipment & ancillary solutions market in the UK is driven by factors such as rising government spending on clinical research and rising number of clinical trial studies in the region. According to the National Institute for Health Research (NIHR), UK, clinical research is worth USD 3.74 billion each year and includes USD 2.07 billion from commercial sources, which supports around 47,000 jobs.

Asia Pacific Clinical Trial Equipment & Ancillary Solutions Market Trends

Asia Pacific is expected to be the fastest growing market due to growing investment by developed countries in the regions and various amendments made by the regulatory agencies to facilitate local manufacturing & contract services.

The clinical trial equipment & ancillary solutions market in China held the largest share in 2024. The growth is attributed to the government initiatives to regulate the clinical trials as per the global standards and better infrastructure, which includes 4,000 hospital beds. Initially in China, Centre of Drug Evaluation (CDE) was responsible was regulating the clinical trials

The clinical trial equipment & ancillary solutions market in Japan is expected to grow over the forecast period. The regulatory process is supportive of faster clinical trial approval. For instance, clinical trials can be started once the probable benefits are demonstrated by carrying out a relatively smaller number of clinical trials.

The clinical trial equipment & ancillary solutions market in India is anticipated to grow at the lucrative CAGR over the forecast period. This can be attributed to the increasing government funds. The government of India focuses on expanding affordable healthcare facilities in the country. This propelled the growth of the clinical trials sector in India. In addition, local Indian players such as Vitas Pharma (Hyderabad) and Bugworks (Bengaluru) ventured into drug development activities.

Key Clinical Trials Equipment & Ancillary Solutions Company Insights

Several key players are acquiring various strategic initiatives to strengthen their market position offering diverse services to customers. The prominent strategies adopted by companies are service launches, mergers & acquisitions/joint ventures merger, partnership & agreements, expansions, and others to increase market presence & revenue and gain a competitive edge drives the market growth.

Recent Developments

• In January 2025, Ancillare announced the launch of its state-of-the-art cold chain management service capabilities for clinical trial supplies. The enhancements focus on maintaining temperature integrity, expanding global logistics capabilities, and incorporating real-time tracking and visibility tools.

• In May 2024, Emsere entered into a partnership agreement with the Clario to enhance ophthalmic imaging capacity in clinical trials by integrating Clario’s clinical trial software with Emsere’s barcoded imaging devices. The expansion addresses needs in retina-focused ophthalmology studies, improving equipment provision and imaging workflow efficiency.

Clinical Trial Equipment & Ancillary Solutions Market